Tolerization to brain and vascular antigens: Targeting autoimmunity after acute brain injuries and preventing stroke

Immunological Mechanisms and Therapies in Brain Injuries and Stroke

Volumn , Issue , 2014, Pages 287-299

  Becker, Kyra J ^a   Hallenbeck, John ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919710691     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-8915-3_16     Document Type: Chapter

References (77)

1. Jander S, Kraemer M, Schroeter M, Witte OW, Stoll G (1995) Lymphocytic infiltration and expression of intercellular adhesion molecule-1 in photochemically induced ischemia of the rat cortex. J Cereb Blood Flow Metab 15(1):42-51
2. Schroeter M, Jander S, Witte OW, Stoll G (1994) Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion. J Neuroimmunol 55(2):195-203
3. Braun JS, Jander S, Schroeter M, Witte OW, Stoll G (1996) Spatiotemporal relationship of apoptotic cell death to lymphomonocytic infiltration in photochemically induced focal ischemia of the rat cerebral cortex. Acta Neuropathol (Berl) 92(3):255-63
4. Campanella M, Sciorati C, Tarozzo G, Beltramo M (2002) Flow cytometric analysis of inflammatory cells in ischemic rat brain. Stroke 33(2):586-92
5. Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ (2000) Release of glial tissue- specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 31(11):2670-7
6. Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR (2006) Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke 37(10): 2508-13
7. van Zwam M, Huizinga R, Melief MJ, Wierenga-Wolf AF, van Meurs M, Voerman JS et al (2009) Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE. J Mol Med 87(3):273-86
8. Planas AM, Gomez-Choco M, Urra X, Gorina R, Caballero M, Chamorro A (2012) Brain- derived antigens in lymphoid tissue of patients with acute stroke. J Immunol 188(5):2156-63
9. Youngchaiyud U, Coates AS, Whittingham S, Mackay IR (1974) Cellular-immune response to myelin protein: absence in multiple sclerosis and presence in cerebrovascular accidents. Aust N Z J Med 4(6):535-8
10. Kallen B, Nilsson O, Thelin C (1977) Effect of encephalitogenic protein on migration in agarose of leukoytes from patients with multiple sclerosis. A longitudinal study of patients with relapsing multiple sclerosis or with cerebral infarction. Acta Neurol Scand 55(1):47-56
11. Rocklin RE, Sheremata WA, Feldman RG, Kies MW, David JR (1971) The Guillain-Barre syndrome and multiple sclerosis. In vitro cellular responses to nervous-tissue antigens. N Engl J Med 284(15):803-8
12. Prass K, Meisel C, Hoflich C, Braun J, Halle E, Wolf T et al (2003) Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 198(5): 725-36
13. Wong CH, Jenne CN, Lee WY, Leger C, Kubes P (2011) Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science 334(6052):101-5
14. Becker K (2012) Autoimmune responses to brain following stroke. Transl Stroke Res
15. Becker KJ, Kindrick DL, Lester MP, Shea C, Ye ZC (2005) Sensitization to brain antigens after stroke is augmented by lipopolysaccharide. J Cereb Blood Flow Metab 25(12):1634-44
16. Zierath D, Thullbery M, Hadwin J, Gee JM, Savos A, Kalil A et al (2010) CNS immune responses following experimental stroke. Neurocrit Care 12(2):274-84
17. Becker KJ, Kalil AJ, Tanzi P, Zierath DK, Savos AV, Gee JM et al (2011) Autoimmune responses to the brain after stroke are associated with worse outcome. Stroke 42:2763-9
18. Gee JM, Kalil A, Thullbery M, Becker KJ (2008) Induction of immunologic tolerance to myelin basic protein prevents central nervous system autoimmunity and improves outcome after stroke. Stroke 39(5):1575-82
19. Gee JM, Zierath D, Hadwin J, Savos A, Kalil A, Thullbery M et al (2009) Long term immunologic consequences of experimental stroke and mucosal tolerance. Exp Transl Stroke Med 1:3
20. Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N et al (2010) Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol 87(3):385-95
21. Westendorp WF, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D (2011) Poststroke infection: a systematic review and meta-analysis. BMC Neurol 11:110
22. Johnston KC, Li JY, Lyden PD, Hanson SK, Feasby TE, Adams RJ et al (1998) Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators. Stroke 29(2):447-53
23. Aslanyan S, Weir CJ, Diener HC, Kaste M, Lees KR (2004) Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial. Eur J Neurol 11(1):49-53
24. Katzan IL, Cebul RD, Husak SH, Dawson NV, Baker DW (2003) The effect of pneumonia on mortality among patients hospitalized for acute stroke. Neurology 60(4):620-5
25. Minnerup J, Wersching H, Brokinkel B, Dziewas R, Heuschmann PU, Nabavi DG et al (2010) The impact of lesion location and lesion size on poststroke infection frequency. J Neurol Neurosurg Psychiatr 81(2):198-202
26. Hug A, Dalpke A, Wieczorek N, Giese T, Lorenz A, Auffarth G et al (2009) Infarct volume is a major determiner of post-stroke immune cell function and susceptibility to infection. Stroke 40(10):3226-32
27. Tanzi P, Cain K, Kalil A, Zierath D, Savos A, Gee JM et al (2011) Post-stroke infection: a role for IL-1ra? Neurocrit Care 14(2):244-52
28. Hong KS, Kang DW, Koo JS, Yu KH, Han MK, Cho YJ et al (2008) Impact of neurological and medical complications on 3-month outcomes in acute ischaemic stroke. Eur J Neurol 15(12):1324-31
29. Vermeij FH, Scholte op Reimer WJ, de Man P, van Oostenbrugge RJ, Franke CL, de Jong G (2009) Stroke-associated infection is an independent risk factor for poor outcome after acute ischemic stroke: data from the Netherlands Stroke Survey. Cerebrovasc Dis 27(5):465-71
30. Oppenheim JJ, Tewary P, de la Rosa G, Yang D (2007) Alarmins initiate host defense. Adv Exp Med Biol 601:185-94
31. Yang D, de la Rosa G, Tewary P, Oppenheim JJ (2009) Alarmins link neutrophils and dendritic cells. Trends Immunol 30(11):531-7
32. Bianchi ME, Manfredi AA (2007) High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 220:35-46
33. Meisel C, Prass K, Braun J, Victorov I, Wolf T, Megow D et al (2004) Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke. Stroke 35(1):2-6
34. Chamorro A, Horcajada JP, Obach V, Vargas M, Revilla M, Torres F et al (2005) The early systemic prophylaxis of infection after stroke study: a randomized clinical trial. Stroke 36(7): 1495-500
35. Harms H, Prass K, Meisel C, Klehmet J, Rogge W, Drenckhahn C et al (2008) Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PLoS One 3(5): e2158
36. Schwarz S, Al-Shajlawi F, Sick C, Meairs S, Hennerici MG (2008) Effects of prophylactic antibiotic therapy with mezlocillin plus sulbactam on the incidence and height of fever after severe acute ischemic stroke: the Mannheim infection in stroke study (MISS). Stroke 39(4):1220-7
37. Savos AV, Gee JM, Zierath D, Becker KJ (2011) alpha-MSH: A potential neuroprotective and immunomodulatory agent for the treatment of stroke. J Cereb Blood Flow Metab 31(2): 606-13
38. Miller A, Lider O, Weiner HL (1991) Antigen-driven bystander suppression after oral administration of antigens. J Exp Med 174(4):791-8
39. Becker KJ, McCarron RM, Ruetzler C, Laban O, Sternberg E, Flanders KC et al (1997) Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia. Proc Natl Acad Sci U S A 94(20):10873-8
40. Becker K, Kindrick D, McCarron R, Hallenbeck J, Winn R (2003) Adoptive transfer of myelin basic protein-tolerized splenocytes to naive animals reduces infarct size: a role for lymphocytes in ischemic brain injury? Stroke 34(7):1809-15
41. Frenkel D, Huang Z, Maron R, Koldzic DN, Moskowitz MA, Weiner HL (2005) Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J Neurol Sci 233(1-2): 125-32
42. Spera PA, Ellison JA, Feuerstein GZ, Barone FC (1998) IL-10 reduces rat brain injury following focal stroke. Neurosci Lett 251(3):189-92
43. Grilli M, Barbieri I, Basudev H, Brusa R, Casati C, Lozza G et al (2000) Interleukin-10 modulates neuronal threshold of vulnerability to ischaemic damage. Eur J Neurosci 12(7):2265-72
44. Zhou Z, Peng X, Insolera R, Fink DJ, Mata M (2009) Interleukin-10 provides direct trophic support to neurons. J Neurochem 110(5):1617-27
45. Justicia C, Perez-Asensio FJ, Burguete MC, Salom JB, Planas AM (2001) Administration of transforming growth factor-alpha reduces infarct volume after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 21(9):1097-104
46. Henrich-Noack P, Prehn JH, Krieglstein J (1996) TGF-beta 1 protects hippocampal neurons against degeneration caused by transient global ischemia. Dose-response relationship and potential neuroprotective mechanisms. Stroke 27(9):1609-14, discussion 15
47. Ma M, Ma Y, Yi X, Guo R, Zhu W, Fan X et al (2008) Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone. BMC Neurosci 9:117
48. Hallenbeck JM, Dutka AJ, Kochanek PM, Siren A, Pezeshkpour GH, Feuerstein G (1988) Stroke risk factors prepare rat brainstem tissues for modified local Shwartzman reaction. Stroke 19(7):863-9
49. Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2(8):675-80
50. Thomas L (1983) The youngest science: notes of a medicine-watcher. Viking, New York
51. Liu Y, Liu T, McCarron RM, Spatz M, Feuerstein G, Hallenbeck JM et al (1996) Evidence for activation of endothelium and monocytes in hypertensive rats. Am J Physiol 270(6 Pt 2): H2125-31
52. Rosenberg RD, Aird WC (1999) Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 340(20):1555-64
53. Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B (1989) Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 243(4895):1160-5
54. Takeda H, Spatz M, Ruetzler C, McCarron R, Becker K, Hallenbeck J (2002) Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke 33(9):2156-63
55. Chen Y, Ruetzler C, Pandipati S, Spatz M, McCarron RM, Becker K et al (2003) Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci U S A 100(25):15107-12
56. Hallenbeck J (2010) How inflammation modulates central nervous system vessel activation and provides targets for intervention-a personal perspective. Ann N Y Acad Sci 1207:1-7
57. Ishibashi S, Maric D, Mou Y, Ohtani R, Ruetzler C, Hallenbeck JM (2009) Mucosal tolerance to E-selectin promotes the survival of newly generated neuroblasts via regulatory T-cell induction after stroke in spontaneously hypertensive rats. J Cereb Blood Flow Metab 29(3):606-20
58. Vila J, Isaacs JD, Anderson AE (2009) Regulatory T cells and autoimmunity. Curr Opin Hematol 16(4):274-9
59. Lee YK, Mukasa R, Hatton RD, Weaver CT (2009) Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 21(3):274-80
60. Xiao BG, Link H (1997) Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol 85(2):119-28
61. Blanas E, Carbone FR, Allison J, Miller JF, Heath WR (1996) Induction of autoimmune diabetes by oral administration of autoantigen. Science 274(5293):1707-9
62. Genain CP, Abel K, Belmar N, Villinger F, Rosenberg DP, Linington C et al (1996) Late complications of immune deviation therapy in a nonhuman primate. Science 274(5295): 2054-7
63. Hafler DA, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Fukaura H (1997) Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. Ann N Y Acad Sci 835:120-31
64. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA (1996) Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor- beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 98(1):70-7
65. Wei W, Zhang LL, Xu JH, Xiao F, Bao CD, Ni LQ et al (2009) A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis. Arthritis Res Ther 11(6):R180
66. Choy EH, Scott DL, Kingsley GH, Thomas S, Murphy AG, Staines N et al (2001) Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum 44(9):1993-7
67. Barnett ML, Kremer JM, St Clair EW, Clegg DO, Furst D, Weisman M et al (1998) Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 41(2):290-7
68. Fourlanos S, Perry C, Gellert SA, Martinuzzi E, Mallone R, Butler J et al (2011) Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 60(4):1237-45
69. Nussenblatt R (2004) Orally and nasally induced tolerance studies in ocular inflammatory disease: guidance for future interventions. Ann N Y Acad Sci 1029:278-85
70. Kraus TA, Mayer L (2005) Oral tolerance and inflammatory bowel disease. Curr Opin Gastroenterol 21(6):692-6
71. Margalit M, Israeli E, Shibolet O, Zigmond E, Klein A, Hemed N et al (2006) A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach. Am J Gastroenterol 101(3): 561-8
72. Ilan Y (2004) Oral immune regulation toward disease-associated antigens: results of phase I clinical trials in Crohn's disease and chronic hepatitis. Ann N Y Acad Sci 1029:286-98
73. Hallenbeck J, Del Zoppo G, Jacobs T, Hakim A, Goldman S, Utz U et al (2006) Immunomodulation strategies for preventing vascular disease of the brain and heart: workshop summary. Stroke 37(12):3035-42
74. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018-28
75. Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353(4):369-74
76. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353(4):375-81
77. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab- associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9(4):438-46